iifl-logo-icon 1
iifl-logo-icon 1

Arvind Remedies Ltd Share Price

₹4.65
(-4.12%)
Jun 13, 2016|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Arvind Remedies Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

₹4.7

Prev. Close

₹4.85

Turnover(Lac.)

₹0.08

Day's High

₹4.7

Day's Low

₹4.65

52 Week's High

₹0

52 Week's Low

₹0

Book Value

₹-27.45

Face Value

₹10

Mkt Cap (₹ Cr.)

31.68

P/E

0

EPS

0

Divi. Yield

0

Arvind Remedies Ltd Corporate Action

No Record Found

Arvind Remedies Ltd NEWS AND UPDATE

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center

Demat Account

View More

Trading Account

View More

Arvind Remedies Ltd SHAREHOLDING SNAPSHOT

09 Oct, 2024|06:14 PM
Jun-2016Mar-2016Sep-2015Jun-2015
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 3.57%

Foreign: 0.00%

Indian: 3.57%

Non-Promoter- 0.02%

Institutions: 0.01%

Non-Institutions: 96.40%

Custodian: 0.00%

Read More
Share Price

Arvind Remedies Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Jun-2015Mar-2014Mar-2013Mar-2012

Equity Capital

68.13

68.13

64.39

48.23

Preference Capital

0

0

0

0

Reserves

-110.41

211.34

129.87

94.86

Net Worth

-42.28

279.47

194.26

143.09

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Jun-2015Mar-2014Mar-2013Mar-2012

Revenue

787.06

911.1

664.26

436.62

yoy growth (%)

-13.61

37.16

52.13

20.43

Raw materials

-790.06

-683.61

-497.08

-347.14

As % of sales

100.38

75.03

74.83

79.5

Employee costs

-15.98

-17.41

-13.44

-9.08

View Profit & Loss
Y/e 31 Mar( In .Cr)Jun-2015Mar-2014Mar-2013Mar-2012

Profit before tax

-137.82

86.39

62.55

37.21

Depreciation

-29.46

-13.9

-12.58

-3.23

Tax paid

5.23

-27.49

-21.93

-17.8

Working capital

-54.91

173.49

115.59

47.78

Other operating items

View Cash Flow
Y/e 31 MarJun-2015Mar-2014Mar-2013Mar-2012

Growth matrix (%)

Revenue growth

-13.61

37.16

52.13

20.43

Op profit growth

-124.38

32.3

97.29

64.34

EBIT growth

-140.82

34.3

87.47

65.81

Net profit growth

-643.37

45

109.25

14.83

View Ratios
Particulars (Rupees in Crores.)Mar-2014Mar-2013Mar-2012

Gross Sales

961.28

704.35

467.07

Excise Duty

0

0

0

Net Sales

961.28

704.35

467.07

Other Operating Income

1.39

1.75

0.64

Other Income

0.54

0.77

0.57

View Annually Results

Arvind Remedies Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,917.15

165.254,59,916.52237.820.74,409.7498.75

Divis Laboratories Ltd

DIVISLAB

5,547.05

88.651,47,255.424300.542,063507.93

Cipla Ltd

CIPLA

1,640.7

33.361,32,489.441,055.940.793,752.25346.39

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,517.45

79.251,19,108.834690.82,394201.77

Dr Reddys Laboratories Ltd

DRREDDY

6,656.05

26.981,11,134.211,417.20.65,823.91,458.55

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

View All Peer Comparision

MORE ABOUT Arvind Remedies Ltd

Management

Register Office

Registrar Office

Managing Director & CEO

B Arvind Shah

Whole-time Director

Chandra Ravindran

Company Secretary

P R Krishnan

Director

Madhav Yadav

Additional Director

Timothy Allen

Additional Director

M Vasudevan

Registered Office

Tel: -

Website: -

Email: -

Registrar Office

Tel: -

Website: -

Email: -

Reports by Arvind Remedies Ltd

Summary

Promoted by Arvind Kumar Shah, C M K Reddy, Chhotalal and Chandra Ravindran Arvind Remedies (ARL) was incorporated in Jun.88 as a private limited company which was later converted into a public limited company in Apr.95.ARL is engaged mainly formulation of Capsules and tablets. It manufactures over 80 products in various segments like ethical, generic and exports, besides institutions in the south. In 1999-2000, the company built up its own manufacturing facility at an expanded capacity of Tablets, Capsules, Liquids, Orals, Ointments, Ayurvedic preparations at Kakkalur, Thiruvallur Dist. under the state-of-the-art technology which is fully operational.In Nov.00, the company came out with a offering to existing shareholders through a rights issue of 14,86,000 equity shares of Rs 10 each at a premium of Rs 90 per share in the ratio of one equity share held for every four shares held.The company entered into an agreement into Bal Pharma Ltd Bangalore for manufacturing products of Bal Pharma Ltd. The company has decided to have a centralised distribution centre, for which it it going use already allotted 3 acres plot,which was allotted by SIDCO. The plans have been drawn to start the civil works and the proposed construction activities are scheduled to be completed in December,2002.
Read More

QUICKLINKS FOR Arvind Remedies Ltd

Information
Share PriceFutures PriceOption ChainHistorical Data
Financials
Profit & LossBalance SheetCash FlowKey Ratios
Results
Quarterly ResultHalf Yearly ResultNine Monthly ResultAnnual Result
News
Company
Market
Derivatives
IPO
Mutual Funds
Calculators
Nifty 50
Company
Loans
Knowledge Center
News
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

About
IIFL Group
Products & Services
Trading Documentation
Useful Links

ATTENTION INVESTORS

  • Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020
  • Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.
  • Pay 20% upfront margin of the transaction value to trade in cash market segment.
  • Investors may please refer to the Exchange’s Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.
  • Check your Securities / MF / Bonds in the consolidated account statement issued by NSDL/CDSL every month.
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day.” – Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets – once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor’s account.

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp